BR112017027350A2 - método para aumentar a solubilidade de estilbenoide, solução aquosa e seu uso e uso de alfa-glucano de redução - Google Patents

método para aumentar a solubilidade de estilbenoide, solução aquosa e seu uso e uso de alfa-glucano de redução

Info

Publication number
BR112017027350A2
BR112017027350A2 BR112017027350A BR112017027350A BR112017027350A2 BR 112017027350 A2 BR112017027350 A2 BR 112017027350A2 BR 112017027350 A BR112017027350 A BR 112017027350A BR 112017027350 A BR112017027350 A BR 112017027350A BR 112017027350 A2 BR112017027350 A2 BR 112017027350A2
Authority
BR
Brazil
Prior art keywords
stilbenoid
solubility
increasing
aqueous solution
alpha
Prior art date
Application number
BR112017027350A
Other languages
English (en)
Other versions
BR112017027350B1 (pt
Inventor
Grentzmann Guido
Original Assignee
Opterion Health Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opterion Health Ag filed Critical Opterion Health Ag
Publication of BR112017027350A2 publication Critical patent/BR112017027350A2/pt
Publication of BR112017027350B1 publication Critical patent/BR112017027350B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

trata-se de uma solução aquosa que compreende, em estado dissolvido, - pelo menos um estilbenoide - pelo menos um sacarídeo, e um método para aumentar a solubilidade de um estilbenoide em água.
BR112017027350-0A 2015-07-20 2016-07-19 Método para aumentar a solubilidade de estilbenoide, solução aquosa e seu uso e uso de alfa-glucano de redução BR112017027350B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15177541.8 2015-07-20
EP15177541.8A EP3120838A1 (en) 2015-07-20 2015-07-20 Aqueous solution comprising a polyphenol
PCT/EP2016/067188 WO2017013121A1 (en) 2015-07-20 2016-07-19 Aqueous solution comprising a stilbenoid

Publications (2)

Publication Number Publication Date
BR112017027350A2 true BR112017027350A2 (pt) 2018-08-28
BR112017027350B1 BR112017027350B1 (pt) 2023-08-01

Family

ID=

Also Published As

Publication number Publication date
PL3324935T3 (pl) 2023-04-24
JP2018521088A (ja) 2018-08-02
CN108601729A (zh) 2018-09-28
CN108601729B (zh) 2022-10-25
HK1254524A1 (zh) 2019-07-19
JP6505310B2 (ja) 2019-04-24
EP3324935A1 (en) 2018-05-30
WO2017013121A1 (en) 2017-01-26
PT3324935T (pt) 2022-11-04
RS63867B1 (sr) 2023-01-31
EP3324935B1 (en) 2022-10-19
US11185514B2 (en) 2021-11-30
US20200108026A1 (en) 2020-04-09
DK3324935T3 (da) 2022-11-28
ES2929527T3 (es) 2022-11-29
EP3120838A1 (en) 2017-01-25
US20180214387A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
CL2017002401A1 (es) Anticuerpos contra icos
CL2016001694A1 (es) Un panel para mobiliario
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017001247A2 (pt) divisores dinâmicos de juntas para janelas de aplicação
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2017000533A1 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112017001315A2 (pt) fundamentos do dispositivo de computação modular
CL2017002521A1 (es) Paginación de sistema de procesamiento de eventos.
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
CO2017003071A2 (es) Sistema de fijación externo para un exoesqueleto ortopédico
AR103077A1 (es) Método para la producción de un sistema de administración farmacéutica
AR098168A1 (es) Formulación estable de insulina glulisina
BR112016024354A2 (pt) gpio virtual híbrida
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112018013832A2 (pt) formulação para a dissolução de ditiazina amorfa e método de uso
CL2016001746A1 (es) Derivados de hidroxi formamida y sus usos
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/07/2016, OBSERVADAS AS CONDICOES LEGAIS